Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REVAXIS · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REVAXIS® | BIOLOGICAL | - |
| DT-Polio® | BIOLOGICAL | - |
Inclusion Criteria: 1. Healthy child without chronic severe disease of either gender, 2. 6 year-old child on vaccination day, 3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life...
REVAXIS is a vaccine used for diphtheria, and it is also studied for tetanus and poliomyelitis. It is being developed by Sanofi (SNY) as a booster vaccine for children. The drug is currently in Phase 3 clinical development and is considered investigational.
REVAXIS is developed by Sanofi, a pharmaceutical company traded under the ticker SNY. The vaccine is being studied for use in diphtheria, tetanus, and poliomyelitis. It is currently in Phase 3 clinical trials.
REVAXIS is in Phase 3 clinical development. It is an investigational vaccine being studied for diphtheria, tetanus, and poliomyelitis. The drug is not yet approved and is still undergoing clinical trials to evaluate its safety and efficacy.
REVAXIS has one completed Phase 3 clinical trial, NCT00447525, which studied the vaccine as a second booster in 6-year-old children. The trial enrolled 760 participants in France and was active-controlled, comparing REVAXIS to DT Polio. The study is completed.
REVAXIS is not the same as DT Polio. In the clinical trial NCT00447525, REVAXIS was compared against DT Polio as an active control. REVAXIS is an investigational vaccine developed by Sanofi, while DT Polio is a separate vaccine used as a comparator in the study.